arrow
V

Vittorio Del Fabro

university of enna kore
H指数:12
被引数:487

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heme oxygenase-1/CO signaling suppresses NLRP3 inflammasome–mediated stromal fibrosis in primary myelofibrosis

血红素加氧酶-1/一氧化碳信号通路抑制NLRP3炎性小体介导的原发性骨髓纤维化

2026-07-200
OAAI
Glutamate accumulation in myelofibrosis microenvironment rewires mesenchymal stromal cells metabolic and epigenetic profiles

谷氨酸在骨髓纤维化微环境中的积累重塑间充质基质细胞的代谢和表观遗传谱

2026-07-090
OA
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironment

周细胞和间充质基质细胞在肿瘤微环境中向促肿瘤表型转化

2026-03-110
OAAI
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers

达鲁单抗、来那度胺和地塞米松在移植不适用的新诊断多发性骨髓瘤患者中的长期生存——一项来自两个意大利中心的研究

2026-02-210
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study

霍奇金炎症基础模型ME-IPS是一种在诊断时计算的新炎症基础预后模型:来自真实世界研究的结果

2025-11-010
PRE
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis
2025-01-140
OAAI
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia

达沙替尼和Selinexor联合治疗慢性粒细胞白血病增强的抗肿瘤活性

2024-07-051
OAAI
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions

在血液学条件下,tixagevimab-cilgavimab与SARS-CoV-2突破性感染的疗效和安全性

CANCER
IF5.1
2023-09-019
PRE
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab

接种和预防tixagevimab/cilgavimab后,多发性骨髓瘤患者发生SARS-CoV-2感染的临床结果

2023-03-298
OAAI
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma

乳酸运输抑制可恢复对蛋白酶体抑制剂的敏感性并协调多发性骨髓瘤的免疫微环境

2023-02-1510
OAAI
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

Daratumumab作为复发/难治性骨髓瘤患者的单一药物: 一项回顾性现实调查

2021-03-058
OAAI
Younger patients with Waldenstrom Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
2020-09-099
OAAI
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

在复发/难治性多发性骨髓瘤患者中使用泊马度胺和地塞米松进行长期疾病控制的临床益处

2019-10-168
OAAI
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
2019-06-1923
OAAI